# A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

> **NCT03836599** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 6 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Verinurad
- **DRUG:** Allopurinol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03836599
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-16
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836599, "A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03836599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*